THOR MEDICAL

AdvanCell Isotopes Pty LtdBiotechAustralia

73% matchAI 0/100Green 0/100

AdvanCell Isotopes Pty Ltd is an Australian medical-isotope company developing technologies to produce isotopes used in targeted radiopharmaceutical cancer treatments. It serves radiopharmaceutical developers, pharmaceutical companies, and nuclear-medicine providers seeking reliable supplies of therapeutic isotopes.

Atley SolutionsBiotechnologySweden

66% match

Atley Solutions is a global leader in commercial products and services for astatine-related (At-211) radiopharmaceutical development and scalable manufacturing, originating from research at the University of Gothenburg.

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Melbourne, Australia, focused on the development of diagnostic and therapeutic radiopharmaceuticals.

radiopharma rival LantheusBiotechnology & Pharmaceuticals

66% match

Lantheus is a radiopharmaceutical-focused company that develops diagnostic and therapeutic products, with a focus on oncology, neurology, and cardiology. The company serves patients and healthcare providers by delivering life-changing science to improve medical outcomes.

Bwxt MedicalPharmaceuticalsCanada

64% match

BWXT Medical Ltd. is a nuclear medicine company headquartered in Kanata, Ontario, with additional operations in Vancouver, British Columbia, providing contract manufacturing services and medical isotopes.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.